Recent Progress In Cancer Research and Development of Novel Therapies, 21-22/11/2016, Ruth Auditorium, Technion, Rappaport Faculty of Medicine

Monday, 21.11.16
08:45 – Introduction, Dean Eliezer Shalev, Eyal Gottleib
Session A: What Went Wrong – Fundamentals of Cancer Signaling: Chair – Asya Rolls
09:00 – Douglas Hanahan, The Swiss Federal Institute of Technology, Lausanne
Mechanistic insights into multistep tumorigenesis and its (evolutionary) adaptations
09:35 – Gad Getz, Broad Institute of MIT and Harvard
What can we learn from cancer genomes?
10:10 – Adi Kimchi, Weizmann Institute of Science
The protein interaction map of autophagy and apoptosis: from basic principles to a therapeutic vision
10:45 – 11:10 Coffee Break
Session A: Continued: Chair – Ruth Hershberg
11:10 – Uri Alon, Weizmann Institute of Science
Evolutionary Tradeoffs and the Geometry of Phenotype Space
11:45 – 12:20 Roy Kishoni, Technion
Understanding, predicting and manipulating the evolution of antibiotic resistance
12:20 – Carlos Caldas, Cambridge Cancer Centre
Modelling Breast Cancer Inter- and Intra-Tumor Heterogeneity Using Patient-Derived Explants
13:00 – 14:30 Lunch
Session B: Cancer Metabolism: Chair – Tomer Shlomi
14:30 – Lewis Cantley, Meyer Cancer Center, Cornell University
PI 3-Kinase and Cancer Metabolism
15:05 – Celeste Simon, University of Pennsylvania
Striking a Balance between Cellular Growth and Homeostasis
15:40 – Eyal Gottlieb, TICC, Faculty of Medicine, Technion
Targeting Metabolic Vulnerabilities of Succinate Dehydrogenase Deficient Tumours
16:15 – 16:40 Coffee Break
Session C: Proteostasis: Chair: Shenhav Cohen
16:40 – Nahum Sonenberg, McGill University, Montreal
Translational control of cancer by eIF4E via the mTOR and MAPK pathways
17:15 – Amir Orian, TICC, Faculty of Medicine, Technion
Specification and maintenance of differentiated cell identity
17:50 – Ze’ev Ronai, Co-Director TICC, Faculty of Medicine, Technion
RNF5 in ER stress and cancer development
18:25 – Aaron Ciechanover, Co-Director TICC, Faculty of Medicine, Technion
Monoubiquitination as a Novel Proteasomal Degradation Signal: Mechanistic and Biomedical Implications

Tuesday, 22.11.2016
Session D: Rewired DNA Damage signaling: Chair – Reut Shalgi
09:00 – Yosef Shiloh, Sackler School of Medicine, Tel Aviv University
The DNA damage response: a matter of checks and balances
09:35 – Varda Rotter, Weizmann Institute of Science
Can mutant p53 change faces into a genome guardian?
10:10 – Moshe Oren, Weizmann Institute of Science
Opposing Effects of RNF20 and Histone H2B Ubiquitylation In Basal-Like Versus Luminal Breast Cancer
10:45 – 11:10 Coffee Break
Session E: Microenvironment: Chair – Yoni Savir
11:10 – 11:45 Michael Karin, University of California, San Diego
Metabolic and Immune Control of Liver Tumorigenesis- From Etiology to Treatment
11:45 – Eli Pikarsky, Faculty of Medicine, The Hebrew University of Jerusalem
Ectopic Lymphoid Structures Function as Microniches for Tumor Progenitor Cells in HCC
12:20 – Yosef Yarden, Weizmann Institute of Science
Playing Chess Against EGFR-driven Lung Cancer
12:55 – Shai Shen-Orr, TICC, Faculty of Medicine, Technion
Equal Protection? Exploring Immune System Variation
13:30-14:45 Lunch
Session F: From Bench to Bedside: Chair – Yehuda Chowers
14:45 – Gad Rennert, TICC, Faculty of Medicine, Technion
Genomic cancer medicine
15:20 – Yuval Shaked, TICC, Faculty of Medicine, Technion
The Yin and Yang Effects of Cancer Therapy
15:55 – Avigdor Scherz, Weizmann Institute of Science
TOOKAD® Soluble VTP: From Local Tumor Ablation to Systemic Cancer Control
16:30 – Uri Sivan, TICC, Russell Berrie Nanotechnology Institute, Technion
A Viable Route to a Massively Parallel Analysis of Individual Cells Extracted from a Tumor
17:05 – 17:30 Coffee Break
Session G: Novel Approaches for Targeting Cancer: Chair – Ron Epelbaum
17:30 – Kevan Shokat, Department of Cell. and Mol. Pharmacology, UCSF
Chemical Strategies for Drugging Undruggable Targets in Oncology
18:05 – Yinon Ben Neriah, Faculty of Medicine, The Hebrew University of Jerusalem
CKIa as a therapeutic target in cancer
18:40 – Keith Flaherty, Dana-Farber/ Harvard Cancer Center
Bringing precision medicine principles to epigenetic states in melanoma
19:15 – Closing Remarks, Wayne D. Kaplan, Executive Vice President for Research